ONIRO

History

ONIRO is a breakthrough, patent-pending, clinically tested nutraceutical designed for optimum weight management, heart health and glucose homeostasis. ONIRO manages caloric uptake through carb control by inhibiting carbohydrate-digesting enzymes and glucose uptake in the small intestine. ONIRO which is a proprietary extract of onions cultivated in the nutrient-rich land of Jeju Island (S. Korea), helps improve heart biomarkers and reduce weight by managing carbohydrate digestion and uptake in the small intestine.

ONIRO is produced in a manner to ensure the highest level of onion-derived bioactive compounds. This is achieved by controlling the pH (for optimum stability of health-beneficial flavonoids) and the temperature (for optimum creation of ARCs – Amadori Rearrangement Compounds).

Backed by a human clinical trial and in vivo pre-clinical studies which have proven its significant health benefits, and possessing a comprehensive safety profile, ONIRO leads the list of proprietary, branded ingredients by offering competitive pricing at the recommended, efficacious dose.

ONIRO Features & Benefits:

o ONIRO is produced by onions that are grown under strict agronomic conditions in the nutrient rich soils of Jeju Island in S. Korea.

o ONIRO is a well-defined modulator of carbohydrate uptake in the small intestine.

o ONIRO is produced using a proprietary extraction method that ensures the maximum

level of bioactive compounds, such as flavonoids and ARCs.

o Metabolic Syndrome Management

o Fat Reduction

o Cholesterol & LDL Cholesterol Reduction

o Carbohydrate Hydrolyzing Enzyme Inhibition

Clinical results

- Intake 300mg 3 times a day for 12 weeks for 56 subjects

- Evaluation of the distribution of abdominal fat through CT

- Evaluation of fat distribution, fat mass, and body mass through DEXA

Table 1: Fat percentage, fat mass, and lean body mass by DEXA Evaluation of placebo and test groups at baseline and 12-week follow-up.

- Significant reduction in body fat and fat mass

Table 2: Abdominal fat areas by CT Evaluation of placebo and test groups at baseline and the 12-week follow-up.

- First Lumbar Vertebra (L1): Significant reduction in whole, visceral, and subcutaneous fat.

- Fourth Lumbar Vertebra (L4): Significant reduction in whole and subcutaneous fat.